XML 18 R5.htm IDEA: XBRL DOCUMENT v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities    
Net earnings including non-controlling interests $ 1,215 $ 509
Adjustments to reconcile net earnings to net cash provided by operating activities    
Depreciation and amortization 586 578
Asset impairment charges 5 105
Deferred income taxes (112) (59)
Equity in earnings of unconsolidated affiliates, net of dividends (8) (18)
Stock compensation expense 138 72
(Gain) loss on asset contributions, sales and investment revaluation, net (85) 150
Other – net 20 (104)
Changes in operating assets and liabilities, net of acquisitions and dispositions    
Segregated investments (177) 1,261
Trade receivables (379) 197
Inventories (298) 2,152
Other current assets (549) (41)
Trade payables (185) (1,157)
Payables to brokerage customers 276 708
Accrued expenses and other payables 852 (397)
Net cash provided by operating activities 1,299 3,956
Cash flows from investing activities    
Capital expenditures (466) (596)
Net assets of businesses acquired 0 (95)
Proceeds from sales of assets, businesses and investments 56 41
Purchases of marketable securities 0 (11)
Proceeds from sales of marketable securities 6 267
Other – net 31 3
Net cash used in investing activities (373) (391)
Cash flows from financing activities    
Long-term debt payments (5) 0
Net repayments under lines of credit agreements (389) (1,057)
Cash dividends (510) (495)
Acquisition of non-controlling interest 0 (4)
Other – net (51) (23)
Net cash used in financing activities (955) (1,579)
Effect of exchange rate on cash, cash equivalents, restricted cash, and restricted cash equivalents (19) 34
(Decrease) increase in cash, cash equivalents, restricted cash, and restricted cash equivalents (48) 2,020
Cash, cash equivalents, restricted cash, and restricted cash equivalents - beginning of period 5,505 3,924
Cash, cash equivalents, restricted cash, and restricted cash equivalents - end of period $ 5,457 $ 5,944